Home The Word Brain My Amedeo FAQ Privacy About   


As of October 2023, Amedeo had
12,263 active subscribers


  Lung Cancer

  Free Subscription


Articles published in PLoS One

Retrieve available abstracts of 254 articles:
HTML format



Single Articles


    January 2023

  1. Expression of Concern: A Rational Diagnostic Algorithm for the Identification of ALK Rearrangement in Lung Cancer: A Comprehensive Study of Surgically Treated Japanese Patients.
    PLoS One. 2023;18:e0278808.
    PubMed    


  2. KIM NW, Seo SM, Yoo ES, Kang AR, et al
    Short-term carcinogenicity study of N-methyl-N-nitrosourea in FVB-Trp53 heterozygous mice.
    PLoS One. 2023;18:e0280214.
    PubMed     Abstract available



  3. Expression of Concern: The low expression of miR-451 predicts a worse prognosis in non-small cell lung cancer cases.
    PLoS One. 2023;18:e0280774.
    PubMed    


  4. ZHU Y, Sun W, Jiang X, Bai R, et al
    Differential effects of WRAP53 transcript variants on non-small cell lung cancer cell behaviors.
    PLoS One. 2023;18:e0281132.
    PubMed     Abstract available


  5. HUANG T, Le D, Yuan L, Xu S, et al
    Machine learning for prediction of in-hospital mortality in lung cancer patients admitted to intensive care unit.
    PLoS One. 2023;18:e0280606.
    PubMed     Abstract available


  6. ELBERS DC, La J, Minot JR, Gramling R, et al
    Sentiment analysis of medical record notes for lung cancer patients at the Department of Veterans Affairs.
    PLoS One. 2023;18:e0280931.
    PubMed     Abstract available


  7. ZHENG Z, Hu Y, Ren Y, Mo G, et al
    Correlation between metastatic patterns and age in patients with metastatic primary liver cancer: A population-based study.
    PLoS One. 2023;18:e0267809.
    PubMed     Abstract available


  8. MAKRAKIS D, Rounis K, Tsigkas AP, Georgiou A, et al
    Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
    PLoS One. 2023;18:e0277708.
    PubMed     Abstract available


  9. WEI M, Wang P, Zhu X, Morishima M, et al
    Electrophysiological evaluation of an anticancer drug gemcitabine on cardiotoxicity revealing down-regulation and modification of the activation gating properties in the human rapid delayed rectifier potassium channel.
    PLoS One. 2023;18:e0280656.
    PubMed     Abstract available


  10. LEE JP, Na JB, Choi HC, Choi HY, et al
    Lobar emphysema ratio of more than 1% in the lobe with lung cancer as poor predictor for recurrence and overall survival in patients with stage I non-small cell lung cancer.
    PLoS One. 2023;18:e0281715.
    PubMed     Abstract available


  11. GILHAM K, Gadermann A, Dummer T, Murphy RA, et al
    Mental health, cancer risk, and the mediating role of lifestyle factors in the CARTaGENE cohort study.
    PLoS One. 2023;18:e0281588.
    PubMed     Abstract available


  12. ANDERSEN BL, Myers J, Blevins T, Park KR, et al
    Depression in association with neutrophil-to-lymphocyte, platelet-to-lymphocyte, and advanced lung cancer inflammation index biomarkers predicting lung cancer survival.
    PLoS One. 2023;18:e0282206.
    PubMed     Abstract available


  13. SAITO T, Hamakawa A, Takahashi H, Muto Y, et al
    Symptom severity trajectories and distresses in patients undergoing video-assisted thoracoscopic lung resection from surgery to the first post-discharge clinic visit.
    PLoS One. 2023;18:e0281998.
    PubMed     Abstract available


  14. WILLIAMS CD, Allo MA, Gu L, Vashistha V, et al
    Health outcomes and healthcare resource utilization among Veterans with stage IV non-small cell lung cancer treated with second-line chemotherapy versus immunotherapy.
    PLoS One. 2023;18:e0282020.
    PubMed     Abstract available


  15. LEI F, Lee E, Shin J, Lee SY, et al
    Non-pharmacological interventions on anxiety and depression in lung cancer patients' informal caregivers: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0282887.
    PubMed     Abstract available


  16. AMAYA-NIETO J, Torres G, Buitrago G
    Prevalence of lung cancer in Colombia and a new diagnostic algorithm using health administrative databases: A real-world evidence study.
    PLoS One. 2023;18:e0269079.
    PubMed     Abstract available


  17. KWAK SH, Kim EK, Kim MH, Lee EH, et al
    Incidentally found resectable lung cancer with the usage of artificial intelligence on chest radiographs.
    PLoS One. 2023;18:e0281690.
    PubMed     Abstract available


  18. LIU M, Wu J, Wang N, Zhang X, et al
    The value of artificial intelligence in the diagnosis of lung cancer: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0273445.
    PubMed     Abstract available


  19. LU Y, Yang H, Cao Y, Wang Y, et al
    A survival model for prognostic prediction based on ferroptosis-associated genes and the association with immune infiltration in lung squamous cell carcinoma.
    PLoS One. 2023;18:e0282888.
    PubMed     Abstract available


  20. DONOVAN MKR, Huang Y, Blume JE, Wang J, et al
    Functionally distinct BMP1 isoforms show an opposite pattern of abundance in plasma from non-small cell lung cancer subjects and controls.
    PLoS One. 2023;18:e0282821.
    PubMed     Abstract available


  21. DODD RH, Sharman AR, Marshall HM, Yap ML, et al
    "What do I think about implementing lung cancer screening? It all depends on how." Acceptability and feasibility of lung cancer screening in Australia: The view of key stakeholders about health system factors.
    PLoS One. 2023;18:e0283939.
    PubMed     Abstract available


  22. WANG LM, Yadav R, Serban M, Arias O, et al
    Validation of an orthotopic non-small cell lung cancer mouse model, with left or right tumor growths, to use in conformal radiotherapy studies.
    PLoS One. 2023;18:e0284282.
    PubMed     Abstract available


  23. DALVI T, Norgaard M, Fryzek JP, Movva N, et al
    Biomarker expression and survival in patients with non-small cell lung cancer receiving adjuvant chemotherapy in Denmark.
    PLoS One. 2023;18:e0284037.
    PubMed     Abstract available


  24. LIU T, Wu S, Fang W, Li H, et al
    Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis.
    PLoS One. 2023;18:e0283719.
    PubMed     Abstract available


  25. SHI Q, Ruan J, Yang YC, Shi XQ, et al
    rs66651343 and rs12909095 confer lung cancer risk by regulating CCNDBP1 expression.
    PLoS One. 2023;18:e0284347.
    PubMed     Abstract available


  26. BOVE S, Fanizzi A, Fadda F, Comes MC, et al
    A CT-based transfer learning approach to predict NSCLC recurrence: The added-value of peritumoral region.
    PLoS One. 2023;18:e0285188.
    PubMed     Abstract available


  27. OROZCO MORALES ML, Rinaldi CA, de Jong E, Lansley SM, et al
    Geldanamycin treatment does not result in anti-cancer activity in a preclinical model of orthotopic mesothelioma.
    PLoS One. 2023;18:e0274364.
    PubMed     Abstract available


  28. VARUDKAR N, Shiffer EM, Oyer JL, Copik A, et al
    Delivery of a novel membrane-anchored Fc chimera enhances NK cell-mediated killing of tumor cells and persistently virus-infected cells.
    PLoS One. 2023;18:e0285532.
    PubMed     Abstract available


  29. MINERVINI F, Kestenholz P, Bertoglio P, Li A, et al
    Role of intrapulmonary lymph nodes in patients with NSCLC and visceral pleural invasion. The VPI 1314 multicenter registry study protocol.
    PLoS One. 2023;18:e0285184.
    PubMed     Abstract available


  30. YAMAMOTO H, Soh J, Okumura N, Suzuki H, et al
    Randomized phase II study of daily versus alternate-day administrations of S-1 for the elderly patients with completely resected pathological stage IA (tumor diameter > 2 cm)-IIIA of non-small cell lung cancer: Setouchi Lung Cancer Group Study 1201.
    PLoS One. 2023;18:e0285273.
    PubMed     Abstract available


  31. SOUSA MS, Martin P, Johnson MJ, Lind M, et al
    Phase II, double blind, placebo controlled, multi-site study to evaluate the safety, feasibility and desirability of conducting a phase III study of anamorelin for anorexia in people with small cell lung cancer: A study protocol (LUANA trial).
    PLoS One. 2023;18:e0285850.
    PubMed     Abstract available


  32. LIN L, Wang D, Chen H
    The characteristics and survival of second primary lung cancer after Hodgkin's lymphoma: A comparison with first primary lung cancer using the SEER database.
    PLoS One. 2023;18:e0285766.
    PubMed     Abstract available


  33. SABIA F, Balbi M, Ledda RE, Milanese G, et al
    Fully automated calcium scoring predicts all-cause mortality at 12 years in the MILD lung cancer screening trial.
    PLoS One. 2023;18:e0285593.
    PubMed     Abstract available


  34. XIONG Z, Han Z, Pan W, Zhu X, et al
    Correlation between chromatin epigenetic-related lncRNA signature (CELncSig) and prognosis, immune microenvironment, and immunotherapy in non-small cell lung cancer.
    PLoS One. 2023;18:e0286122.
    PubMed     Abstract available


  35. WEN MJ, Hsu HL, Chang CL, Wang JH, et al
    Understanding the medication experience of patients with advanced non-small cell lung cancer taking epidermal growth factor receptor-tyrosine kinase inhibitors: A phenomenological study.
    PLoS One. 2023;18:e0286333.
    PubMed     Abstract available


  36. VAINER G, Huang L, Emancipator K, Nuti S, et al
    Equivalence of laboratory-developed test and PD-L1 IHC 22C3 pharmDx across all combined positive score indications.
    PLoS One. 2023;18:e0285764.
    PubMed     Abstract available


  37. LI W, Wan L
    A trial-based cost-utility analysis of sugemalimab vs. placebo as consolidation therapy for unresectable stage III NSCLC in China.
    PLoS One. 2023;18:e0286595.
    PubMed     Abstract available


  38. UCHINOMIYA K, Tomita M
    A mathematical model for cancer risk and accumulation of mutations caused by replication errors and external factors.
    PLoS One. 2023;18:e0286499.
    PubMed     Abstract available


  39. DIAS MARQUES V, Massago M, da Silva MT, Roskowski I, et al
    Exploring regional disparities in lung cancer mortality in a Brazilian state: A cross-sectional ecological study.
    PLoS One. 2023;18:e0287371.
    PubMed     Abstract available


  40. LIU A, Wang X, Hu L, Yan D, et al
    A predictive molecular signature consisting of lncRNAs associated with cellular senescence for the prognosis of lung adenocarcinoma.
    PLoS One. 2023;18:e0287132.
    PubMed     Abstract available


  41. KIM Y, Ahn B, Yoon S, Lee G, et al
    An oncogenic CTNNB1 mutation is predictive of post-operative recurrence-free survival in an EGFR-mutant lung adenocarcinoma.
    PLoS One. 2023;18:e0287256.
    PubMed     Abstract available


  42. LIU L, Ren W, Du L, Xu K, et al
    LINC01117 inhibits invasion and migration of lung adenocarcinoma through influencing EMT process.
    PLoS One. 2023;18:e0287926.
    PubMed     Abstract available


  43. GODDE K, Fugemann H, Goerling U, Grittner U, et al
    Feasibility of a patient-oriented navigation programme for patients with lung cancer or stroke in Germany: Protocol of the CoreNAVI study.
    PLoS One. 2023;18:e0287638.
    PubMed     Abstract available


  44. PRITCHETT MA, Sigal B, Bowling MR, Kurman JS, et al
    Assessing a biomarker's ability to reduce invasive procedures in patients with benign lung nodules: Results from the ORACLE study.
    PLoS One. 2023;18:e0287409.
    PubMed     Abstract available


  45. SHAO MM, Zhai K, Huang ZY, Yi FS, et al
    Characterization of the alternative splicing landscape in lung adenocarcinoma reveals novel prognosis signature associated with B cells.
    PLoS One. 2023;18:e0279018.
    PubMed     Abstract available


  46. FONG M, Kaner E, Rowland M, Graham HE, et al
    The effect of preoperative behaviour change interventions on pre- and post-surgery health behaviours, health outcomes, and health inequalities in adults: A systematic review and meta-analyses.
    PLoS One. 2023;18:e0286757.
    PubMed     Abstract available


  47. LIU T, Cui L, He Z, Chen Z, et al
    Epidemiology and nomogram of pediatric and young adulthood osteosarcoma patients with synchronous lung metastasis: A SEER analysis.
    PLoS One. 2023;18:e0288492.
    PubMed     Abstract available


  48. LI X, Jansaker F, Sundquist J, Crump C, et al
    Neighborhood deprivation in relation to lung cancer in individuals with type 2 diabetes-A nationwide cohort study (2005-2018).
    PLoS One. 2023;18:e0288959.
    PubMed     Abstract available


  49. KIM JJ, Sayed ME, Ahn A, Slusher AL, et al
    Dynamics of TERT regulation via alternative splicing in stem cells and cancer cells.
    PLoS One. 2023;18:e0289327.
    PubMed     Abstract available


  50. PARKER K, Colhoun S, Bartholomew K, Sandiford P, et al
    Invitation methods for Indigenous New Zealand Maori in lung cancer screening: Protocol for a pragmatic cluster randomized controlled trial.
    PLoS One. 2023;18:e0281420.
    PubMed     Abstract available


  51. GHEMRAWI R, Al Qassem A, Ramadan A, Aldulaymi R, et al
    DNA and protein methyltransferases inhibition by adenosine dialdehyde reduces the proliferation and migration of breast and lung cancer cells by downregulating autophagy.
    PLoS One. 2023;18:e0288791.
    PubMed     Abstract available


  52. NGAMDU KS, Ghosalkar DS, Chung HE, Christensen JL, et al
    Long-term statin therapy is associated with severe coronary artery calcification.
    PLoS One. 2023;18:e0289111.
    PubMed     Abstract available


  53. MOHAMED TIA, Oyelade ON, Ezugwu AE
    Automatic detection and classification of lung cancer CT scans based on deep learning and ebola optimization search algorithm.
    PLoS One. 2023;18:e0285796.
    PubMed     Abstract available


  54. YATANI A, Katsurada N, Fukui T, Yamada J, et al
    Diagnostic yield and the number of tumor cells of ultrathin bronchoscopy for peripheral lung lesions: A comparison with thin bronchoscopy.
    PLoS One. 2023;18:e0290609.
    PubMed     Abstract available


  55. DOWLING LM, Roach P, Magnussen EA, Kohler A, et al
    Fourier Transform Infrared microspectroscopy identifies single cancer cells in blood. A feasibility study towards liquid biopsy.
    PLoS One. 2023;18:e0289824.
    PubMed     Abstract available


  56. LIU Y
    Identification and comprehensive analysis of super-enhancer related genes involved in epithelial-to-mesenchymal transition in lung adenocarcinoma.
    PLoS One. 2023;18:e0291088.
    PubMed     Abstract available


  57. ZHOU D, Zhai X, Zhang R
    Ribonucleotide reductase regulatory subunit M2 (RRM2) as a potential sero-diagnostic biomarker in non-small cell lung cancer.
    PLoS One. 2023;18:e0291461.
    PubMed     Abstract available


  58. DAEI SORKHABI A, Fazlollahi A, Sarkesh A, Aletaha R, et al
    Efficacy and safety of veliparib plus chemotherapy for the treatment of lung cancer: A systematic review of clinical trials.
    PLoS One. 2023;18:e0291044.
    PubMed     Abstract available


  59. WU M, Liu S, Wang C, Wu Y, et al
    Risk factors for mortality among lung cancer patients with covid-19 infection: A systematic review and meta-analysis.
    PLoS One. 2023;18:e0291178.
    PubMed     Abstract available


  60. LIU Y, Yan M
    Trends in all causes and cause specific mortality attributable to ambient particulate matter pollution in China from 1990 to 2019: A secondary data analysis study.
    PLoS One. 2023;18:e0291262.
    PubMed     Abstract available



  61. Retraction: Frondoside A Suppressive Effects on Lung Cancer Survival, Tumor Growth, Angiogenesis, Invasion, and Metastasis.
    PLoS One. 2023;18:e0291478.
    PubMed    


  62. FUJIKAWA K, Saito T, Kurose K, Kojima T, et al
    Integrated analysis of phase 1a and 1b randomized controlled trials; Treg-targeted cancer immunotherapy with the humanized anti-CCR4 antibody, KW-0761, for advanced solid tumors.
    PLoS One. 2023;18:e0291772.
    PubMed     Abstract available


  63. LEROY K, Audigier Valette C, Alexandre J, Boussemart L, et al
    Retrospective analysis of real-world data to evaluate actionability of a comprehensive molecular profiling panel in solid tumor tissue samples (REALM study).
    PLoS One. 2023;18:e0291495.
    PubMed     Abstract available


  64. BINGHAM SL, Small S, Semple CJ
    A qualitative evaluation of a multi-modal cancer prehabilitation programme for colorectal, head and neck and lung cancers patients.
    PLoS One. 2023;18:e0277589.
    PubMed     Abstract available


  65. IKEMOTO S, Sakurai F, Tokuoka S, Yamashita T, et al
    Novel conditionally replicating adenovirus-mediated efficient detection of circulating tumor cells in lung cancer patients.
    PLoS One. 2023;18:e0286323.
    PubMed     Abstract available


  66. WESTEEL V, Schuette W, Urban T, Radonjic D, et al
    Safety and tolerability of weekly docetaxel plus nintedanib: A phase I trial after first-line chemotherapy failure in NSCLC.
    PLoS One. 2023;18:e0292307.
    PubMed     Abstract available


  67. ROUNIS K, Makrakis D, Papadaki C, Monastirioti A, et al
    Correction: Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    PLoS One. 2023;18:e0294382.
    PubMed     Abstract available


  68. MAKRAKIS D, Rounis K, Tsigkas AP, Georgiou A, et al
    Correction: Effect of body tissue composition on the outcome of patients with metastatic non-small cell lung cancer treated with PD-1/PD-L1 inhibitors.
    PLoS One. 2023;18:e0294384.
    PubMed     Abstract available


  69. PENG B, Ling X, Huang T, Wan J, et al
    HSP70 via HIF-1 alpha SUMOylation inhibits ferroptosis inducing lung cancer recurrence after insufficient radiofrequency ablation.
    PLoS One. 2023;18:e0294263.
    PubMed     Abstract available


  70. LIMBU S, McCloskey KE
    Stemness genes and miR-1247-3p expression associate with clinicopathological parameters and prognosis in lung adenocarcinoma.
    PLoS One. 2023;18:e0294171.
    PubMed     Abstract available


  71. AIN NAZIR NU, Shaukat MH, Luo R, Abbas SR, et al
    Novel breath biomarkers identification for early detection of hepatocellular carcinoma and cirrhosis using ML tools and GCMS.
    PLoS One. 2023;18:e0287465.
    PubMed     Abstract available


  72. NIBID L, Greco C, Cordelli E, Sabarese G, et al
    Deep pathomics: A new image-based tool for predicting response to treatment in stage III non-small cell lung cancer.
    PLoS One. 2023;18:e0294259.
    PubMed     Abstract available


    January 2022
  73. VANNINI I, Ferracin M, Fabbri F, Fabbri M, et al
    Overexpression of ultraconserved region 83- induces lung cancer tumorigenesis.
    PLoS One. 2022;17:e0261464.
    PubMed     Abstract available


  74. MENG G, Liu X, Ma T, Lv D, et al
    Predictive value of tumor mutational burden for immunotherapy in non-small cell lung cancer: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0263629.
    PubMed     Abstract available


  75. PATEL YS, Hanna WC, Fahim C, Shargall Y, et al
    RAVAL trial: Protocol of an international, multi-centered, blinded, randomized controlled trial comparing robotic-assisted versus video-assisted lobectomy for early-stage lung cancer.
    PLoS One. 2022;17:e0261767.
    PubMed     Abstract available


  76. NINOMIYA K, Arimura H, Yoshitake T, Hirose TA, et al
    Synergistic combination of a topologically invariant imaging signature and a biomarker for the accurate prediction of symptomatic radiation pneumonitis before stereotactic ablative radiotherapy for lung cancer: A retrospective analysis.
    PLoS One. 2022;17:e0263292.
    PubMed     Abstract available


  77. OTTE R, Roodbeen R, Boland G, Noordman J, et al
    Affective communication with patients with limited health literacy in the palliative phase of COPD or lung cancer: Analysis of video-recorded consultations in outpatient care.
    PLoS One. 2022;17:e0263433.
    PubMed     Abstract available


  78. TAKADA K, Shimokawa M, Takamori S, Shimamatsu S, et al
    The clinical impact of concomitant medication use on the outcome of postoperative recurrent non-small-cell lung cancer in patients receiving immune checkpoint inhibitors.
    PLoS One. 2022;17:e0263247.
    PubMed     Abstract available


  79. WILLIAMSON DFK, Marris SRN, Rojas-Rudilla V, Bruce JL, et al
    Detection of EGFR mutations in non-small cell lung cancer by droplet digital PCR.
    PLoS One. 2022;17:e0264201.
    PubMed     Abstract available


  80. ALHAKAMY NA, Okbazghi SZ, A Alfaleh M, H Abdulaal W, et al
    Wasp venom peptide improves the proapoptotic activity of alendronate sodium in A549 lung cancer cells.
    PLoS One. 2022;17:e0264093.
    PubMed     Abstract available


  81. KARADZOVSKA-KOTEVSKA M, Brunnstrom H, Kosieradzki J, Ek L, et al
    Feasibility of EBUS-TBNA for histopathological and molecular diagnostics of NSCLC-A retrospective single-center experience.
    PLoS One. 2022;17:e0263342.
    PubMed     Abstract available


  82. LI F, Ye P, Cai P, Dong D, et al
    Prevalence of targeted therapy-related genetic variations in NSCLC and their relationship with clinicopathological characteristics.
    PLoS One. 2022;17:e0262822.
    PubMed     Abstract available


  83. WATANABE Y, Nakagawa T, Fukai K, Honda T, et al
    Descriptive study of chest x-ray examination in mandatory annual health examinations at the workplace in Japan.
    PLoS One. 2022;17:e0262404.
    PubMed     Abstract available


  84. KAEWJANTHONG P, Sooksai S, Sasano H, Hutvagner G, et al
    Cell-penetrating peptides containing the progesterone receptor polyproline domain inhibits EGF signaling and cell proliferation in lung cancer cells.
    PLoS One. 2022;17:e0264717.
    PubMed     Abstract available


  85. LIANG H, Peng J
    LncRNA HOTAIR promotes proliferation, invasion and migration in NSCLC cells via the CCL22 signaling pathway.
    PLoS One. 2022;17:e0263997.
    PubMed     Abstract available


  86. MIURA K
    Stiffness reduction and collagenase resistance of aging lungs measured using scanning acoustic microscopy.
    PLoS One. 2022;17:e0263926.
    PubMed     Abstract available


  87. WEBER JD, Spiro JE, Scheffler M, Wolf J, et al
    Reproducibility of dynamic contrast enhanced MRI derived transfer coefficient Ktrans in lung cancer.
    PLoS One. 2022;17:e0265056.
    PubMed     Abstract available


  88. YE W, Huang T
    Correlation analysis of m6A-modified regulators with immune microenvironment infiltrating cells in lung adenocarcinoma.
    PLoS One. 2022;17:e0264384.
    PubMed     Abstract available


  89. LIMA KYN, Cancela MC, de Souza DLB
    Spatial assessment of advanced-stage diagnosis and lung cancer mortality in Brazil.
    PLoS One. 2022;17:e0265321.
    PubMed     Abstract available


  90. LIU H, Li T, Dong C, Lyu J, et al
    Identification of miRNA signature for predicting the prognostic biomarker of squamous cell lung carcinoma.
    PLoS One. 2022;17:e0264645.
    PubMed     Abstract available


  91. OSE N, Takeuchi Y, Sakamaki Y, Kadota Y, et al
    Detection of lymph node metastasis in non-small cell lung cancer using the new system of one-step nucleic acid amplification assay.
    PLoS One. 2022;17:e0265603.
    PubMed     Abstract available


  92. JEGANATHAN V, Knight S, Bricknell M, Ridgers A, et al
    Impact of smoking status and chronic obstructive pulmonary disease on pulmonary complications post lung cancer surgery.
    PLoS One. 2022;17:e0266052.
    PubMed     Abstract available


  93. DALAH EZ, Obaideen A, Anam S, Alzimami K, et al
    Gender based lung cancer risks for symptomatic coronary artery disease patients undergone cardiac CT.
    PLoS One. 2022;17:e0265609.
    PubMed     Abstract available


  94. FREDRIKSEN V, Sevle SOM, Pedersen A, Lango T, et al
    Teacher-student approach for lung tumor segmentation from mixed-supervised datasets.
    PLoS One. 2022;17:e0266147.
    PubMed     Abstract available


  95. GAROFALO M, Jeon YJ, Nuovo GJ, Middleton J, et al
    Correction: MiR-34a/c-Dependent PDGFR-alpha/beta Downregulation Inhibits Tumorigenesis and Enhances TRAIL-Induced Apoptosis in Lung Cancer.
    PLoS One. 2022;17:e0267628.
    PubMed     Abstract available


  96. SQUARA PA, Luu VP, Perol D, Coudert B, et al
    Personalized Reimbursement Model (PRM) program: A real-world data platform of cancer drugs use to improve and personalize drug pricing and reimbursement in France.
    PLoS One. 2022;17:e0267242.
    PubMed     Abstract available


  97. HO HL, Jiang Y, Chiang CL, Karwowska S, et al
    Efficacy of liquid biopsy for disease monitoring and early prediction of tumor progression in EGFR mutation-positive non-small cell lung cancer.
    PLoS One. 2022;17:e0267362.
    PubMed     Abstract available


  98. MIAO J, Wei H, Cui J, Zhang Q, et al
    The prognosis of different distant metastases pattern in malignant tumors of the adrenal glands: A population-based retrospective study.
    PLoS One. 2022;17:e0264431.
    PubMed     Abstract available


  99. SUNG HW, Choi SE, Chu CH, Ouyang M, et al
    Sensitizing drug-resistant cancer cells from blood using microfluidic electroporator.
    PLoS One. 2022;17:e0264907.
    PubMed     Abstract available


  100. LOPEZ-JIMENEZ T, Duarte-Salles T, Plana-Ripoll O, Recalde M, et al
    Association between metabolic syndrome and 13 types of cancer in Catalonia: A matched case-control study.
    PLoS One. 2022;17:e0264634.
    PubMed     Abstract available


  101. CIERESZKO A, Dietrich MA, Slowinska M, Nynca J, et al
    Application of two-dimensional difference gel electrophoresis to identify protein changes between center, margin, and adjacent non-tumor tissues obtained from non-small-cell lung cancer with adenocarcinoma or squamous cell carcinoma subtype.
    PLoS One. 2022;17:e0268073.
    PubMed     Abstract available


  102. CHO KS, Kim S, Chun HB, Cheon JH, et al
    Efficient gene transfection to lung cancer cells via Folate-PEI-Sorbitol gene transporter.
    PLoS One. 2022;17:e0266181.
    PubMed     Abstract available


  103. LEISER D, Samanta S, Strauss J, Eley J, et al
    Correction: Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer.
    PLoS One. 2022;17:e0268256.
    PubMed     Abstract available


  104. POH J, Ngeow KC, Pek M, Tan KH, et al
    Analytical and clinical validation of an amplicon-based next generation sequencing assay for ultrasensitive detection of circulating tumor DNA.
    PLoS One. 2022;17:e0267389.
    PubMed     Abstract available


  105. BIZZO BC, Ebrahimian S, Walters ME, Michalski MH, et al
    Validation pipeline for machine learning algorithm assessment for multiple vendors.
    PLoS One. 2022;17:e0267213.
    PubMed     Abstract available


  106. LI S, Counter CM
    Non-canonical genomic driver mutations of urethane carcinogenesis.
    PLoS One. 2022;17:e0267147.
    PubMed     Abstract available


  107. CHEN Z, Xiong H, Shen H, You Q, et al
    Autophagy characteristics and establishment of autophagy prognostic models in lung adenocarcinoma and lung squamous cell carcinoma.
    PLoS One. 2022;17:e0266070.
    PubMed     Abstract available


  108. PAEZ R, Shah C, Cords AJ, Muterspaugh A, et al
    18F-FSPG PET imaging for the evaluation of indeterminate pulmonary nodules.
    PLoS One. 2022;17:e0265427.
    PubMed     Abstract available


  109. OSAWA T, Abe T, Kikuchi H, Matsumoto R, et al
    Validation of an online application to identify potential immune-related adverse events associated with immune checkpoint inhibitors based on the patient's symptoms.
    PLoS One. 2022;17:e0265230.
    PubMed     Abstract available


  110. WANG H, Li C, Yang R, Jin J, et al
    Prognostic value of the platelet-to-lymphocyte ratio in lung cancer patients receiving immunotherapy: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0268288.
    PubMed     Abstract available


  111. KRAWCZYK P, Grzycka-Kowalczyk L, Blach J, Reszka K, et al
    The efficacy of T790M mutation testing in liquid biopsy-Real clinic data.
    PLoS One. 2022;17:e0267846.
    PubMed     Abstract available


  112. MURCHISON JT, Ritchie G, Senyszak D, Nijwening JH, et al
    Validation of a deep learning computer aided system for CT based lung nodule detection, classification, and growth rate estimation in a routine clinical population.
    PLoS One. 2022;17:e0266799.
    PubMed     Abstract available


  113. KIM Y, Zhu L, Zhu H, Li X, et al
    Characterizing cancer and COVID-19 outcomes using electronic health records.
    PLoS One. 2022;17:e0267584.
    PubMed     Abstract available


  114. PATEL P, Raval M, Manvar A, Airao V, et al
    Lung cancer targeting efficiency of Silibinin loaded Poly Caprolactone /Pluronic F68 Inhalable nanoparticles: In vitro and In vivo study.
    PLoS One. 2022;17:e0267257.
    PubMed     Abstract available


  115. LUGTU EJ, Ramos DB, Agpalza AJ, Cabral EA, et al
    Artificial neural network in the discrimination of lung cancer based on infrared spectroscopy.
    PLoS One. 2022;17:e0268329.
    PubMed     Abstract available


  116. KOSKINEN A, Hemminki O, Forsti A, Hemminki K, et al
    Incidence and survival in laryngeal and lung cancers in Finland and Sweden through a half century.
    PLoS One. 2022;17:e0268922.
    PubMed     Abstract available


  117. KISHI N, Matsuo Y, Hanazawa H, Iizuka Y, et al
    Lack of an association between marital status and survival in patients receiving stereotactic body radiotherapy for early-stage non-small-cell lung cancer.
    PLoS One. 2022;17:e0269463.
    PubMed     Abstract available


  118. SPINI A, Rosellini P, Bellan C, Furiesi F, et al
    Development and validation of a case-finding algorithm for the identification of non-small cell lung cancers in a region-wide Italian pathology registry.
    PLoS One. 2022;17:e0269232.
    PubMed     Abstract available


  119. TANG Y, Luo J, Yang Y, Liu S, et al
    Overexpression of p-4EBP1 associates with p-eIF4E and predicts poor prognosis for non-small cell lung cancer patients with resection.
    PLoS One. 2022;17:e0265465.
    PubMed     Abstract available


  120. PAGE R, Patil D, Akolkar D, Murthy SS, et al
    Circulating tumor cell assay to non-invasively evaluate PD-L1 and other therapeutic targets in multiple cancers.
    PLoS One. 2022;17:e0270139.
    PubMed     Abstract available


  121. LI P, Wang Q, Liu L, Zhou R, et al
    Efficacy and safety of oral Chinese medicine on cancer-related fatigue for lung cancer patients after chemotherapy: Protocol for systematic review and meta-analysis.
    PLoS One. 2022;17:e0270203.
    PubMed     Abstract available


  122. JIANG X, Chen J, Zheng M, Jia H, et al
    Cost-effectiveness analysis of durvalumab as a maintenance treatment for patients with locally advanced, unresectable, stage nsclc in china.
    PLoS One. 2022;17:e0270118.
    PubMed     Abstract available


  123. XIONG Z, Jiang Y, Tian D, Zhang J, et al
    Radiomics for identifying lung adenocarcinomas with predominant lepidic growth manifesting as large pure ground-glass nodules on CT images.
    PLoS One. 2022;17:e0269356.
    PubMed     Abstract available


  124. KIM C, Kwack T, Kim W, Cha J, et al
    Accuracy of two deep learning-based reconstruction methods compared with an adaptive statistical iterative reconstruction method for solid and ground-glass nodule volumetry on low-dose and ultra-low-dose chest computed tomography: A phantom study.
    PLoS One. 2022;17:e0270122.
    PubMed     Abstract available


  125. CASTAGNOLI F, Doran S, Lunn J, Minchom A, et al
    Splenic volume as a predictor of treatment response in patients with non-small cell lung cancer receiving immunotherapy.
    PLoS One. 2022;17:e0270950.
    PubMed     Abstract available


  126. MAZZONE P, Dotson T, Wahidi MM, Bernstein M, et al
    Clinical validation and utility of Percepta GSC for the evaluation of lung cancer.
    PLoS One. 2022;17:e0268567.
    PubMed     Abstract available


  127. BEDERKA LH, Sanchez JR, Rebeles J, Araujo PR, et al
    Sputum analysis by flow cytometry; an effective platform to analyze the lung environment.
    PLoS One. 2022;17:e0272069.
    PubMed     Abstract available


  128. SCHAD F, Thronicke A, Steele ML, Merkle A, et al
    Correction: Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis.
    PLoS One. 2022;17:e0273387.
    PubMed     Abstract available


  129. CHU CH, Huang YH, Lee PH, Hsu KH, et al
    Various impacts of driver mutations on the PD-L1 expression of NSCLC.
    PLoS One. 2022;17:e0273207.
    PubMed     Abstract available


  130. DU H, Zhang T, Lu X, Chen M, et al
    Glycemic index, glycemic load, and lung cancer risk: A meta-analysis of cohort and case-control studies.
    PLoS One. 2022;17:e0273943.
    PubMed     Abstract available


  131. WU M, Liu S, Yang Y, Lin J, et al
    Clinical characteristics and outcomes of lung cancer patients with COVID-19: A systematic review and meta-analysis protocol.
    PLoS One. 2022;17:e0273691.
    PubMed     Abstract available


  132. KIM C, Kim H, Kim SW, Goh Y, et al
    A study of quantitative indicators for slice sorting in cine-mode 4DCT.
    PLoS One. 2022;17:e0272639.
    PubMed     Abstract available


  133. ABDELWAHAB O, Awad N, Elserafy M, Badr E, et al
    A feature selection-based framework to identify biomarkers for cancer diagnosis: A focus on lung adenocarcinoma.
    PLoS One. 2022;17:e0269126.
    PubMed     Abstract available


  134. PROKOPIDIS K, Giannos P, Witard OC, Peckham D, et al
    Aberrant mitochondrial homeostasis at the crossroad of musculoskeletal ageing and non-small cell lung cancer.
    PLoS One. 2022;17:e0273766.
    PubMed     Abstract available


  135. KOCJAN J, Gzik-Zroska B, Nowakowska-Lipiec K, Burkacki M, et al
    Thoracic surgery may alter body static balance via diaphragm dysfunction.
    PLoS One. 2022;17:e0273641.
    PubMed     Abstract available


  136. WAYNE MT, Prescott HC, Arenberg DA
    Prevalence and consequences of non-adherence to an evidence-based approach for incidental pulmonary nodules.
    PLoS One. 2022;17:e0274107.
    PubMed     Abstract available


  137. SHIM YB, Byun JY, Lee JY, Lee EK, et al
    Economic burden of brain metastases in non-small cell lung cancer patients in South Korea: A retrospective cohort study using nationwide claims data.
    PLoS One. 2022;17:e0274876.
    PubMed     Abstract available


  138. DAI L, Mugaanyi J, Zhang T, Tong J, et al
    A pan-cancer bioinformatic analysis of the carcinogenic role of SMARCA1 in human carcinomas.
    PLoS One. 2022;17:e0274823.
    PubMed     Abstract available


  139. LEE JH, Hwang EJ, Lim WH, Goo JM, et al
    Determination of the optimum definition of growth evaluation for indeterminate pulmonary nodules detected in lung cancer screening.
    PLoS One. 2022;17:e0274583.
    PubMed     Abstract available


  140. DUNLOP KLA, Marshall HM, Stone E, Sharman AR, et al
    Motivation is not enough: A qualitative study of lung cancer screening uptake in Australia to inform future implementation.
    PLoS One. 2022;17:e0275361.
    PubMed     Abstract available


  141. KIM S, Jeong WK, Choi JH, Kim JH, et al
    Development of deep learning-assisted overscan decision algorithm in low-dose chest CT: Application to lung cancer screening in Korean National CT accreditation program.
    PLoS One. 2022;17:e0275531.
    PubMed     Abstract available


  142. KRIZOVA L, Safarikova M, Kalousova M, Pfeiferova L, et al
    New methodology of TMB assessment from tissue and liquid biopsy in NSCLC.
    PLoS One. 2022;17:e0275121.
    PubMed     Abstract available


  143. OBROCHTA CA, Parada H Jr, Murphy JD, Nara A, et al
    The impact of patient travel time on disparities in treatment for early stage lung cancer in California.
    PLoS One. 2022;17:e0272076.
    PubMed     Abstract available


  144. BANAGANAPALLI B, Mallah B, Alghamdi KS, Albaqami WF, et al
    Integrative weighted molecular network construction from transcriptomics and genome wide association data to identify shared genetic biomarkers for COPD and lung cancer.
    PLoS One. 2022;17:e0274629.
    PubMed     Abstract available


  145. SAIHOOD A, Karshenas H, Nilchi ARN
    Deep fusion of gray level co-occurrence matrices for lung nodule classification.
    PLoS One. 2022;17:e0274516.
    PubMed     Abstract available


  146. WANG X, Katz S, Miura J, Karakousis G, et al
    A single-center retrospective cohort study of perioperative systemic chemotherapy in diffuse malignant peritoneal mesothelioma.
    PLoS One. 2022;17:e0275187.
    PubMed     Abstract available


  147. WANG BC, Zhang WX, Kuang BH, Lin GH, et al
    The efficacy and tolerability of combining pemetrexed-based chemotherapy with gefitinib in the first-line treatment of non-small cell lung cancer with mutated EGFR: A pooled analysis of randomized clinical trials.
    PLoS One. 2022;17:e0275919.
    PubMed     Abstract available


  148. SANDLIN CW, Gu S, Xu J, Deshpande C, et al
    Epithelial cell size dysregulation in human lung adenocarcinoma.
    PLoS One. 2022;17:e0274091.
    PubMed     Abstract available


  149. NEMLANDER E, Rosenblad A, Abedi E, Ekman S, et al
    Lung cancer prediction using machine learning on data from a symptom e-questionnaire for never smokers, formers smokers and current smokers.
    PLoS One. 2022;17:e0276703.
    PubMed     Abstract available


  150. CHOW YP, Zainul Abidin N, Kow KS, Tho LM, et al
    Analytical and clinical validation of a custom 15-gene next-generation sequencing panel for the evaluation of circulating tumor DNA mutations in patients with advanced non-small-cell lung cancer.
    PLoS One. 2022;17:e0276161.
    PubMed     Abstract available


  151. WU L, Zhuang J, Chen W, Tang Y, et al
    Data augmentation based on multiple oversampling fusion for medical image segmentation.
    PLoS One. 2022;17:e0274522.
    PubMed     Abstract available


  152. JIMENEZ-RAMIREZ C, Gilbert Weber D, Aguilar-Madrid G, Brik A, et al
    Assessment of miR-103a-3p in leukocytes-No diagnostic benefit in combination with the blood-based biomarkers mesothelin and calretinin for malignant pleural mesothelioma diagnosis.
    PLoS One. 2022;17:e0275936.
    PubMed     Abstract available


  153. KLEINSCHMIDT SE, Andres KL, Holen BM, Buehrer BD, et al
    Mortality among mine and mill workers exposed to respirable crystalline silica.
    PLoS One. 2022;17:e0274103.
    PubMed     Abstract available


  154. PITTER JG, Moizs M, Ezer ES, Lukacs G, et al
    Improved survival of non-small cell lung cancer patients after introducing patient navigation: A retrospective cohort study with propensity score weighted historic control.
    PLoS One. 2022;17:e0276719.
    PubMed     Abstract available


  155. DOS SANTOS CF, Braz MG, de Arruda NM, Caram L, et al
    DNA damage and antioxidant capacity in COPD patients with and without lung cancer.
    PLoS One. 2022;17:e0275873.
    PubMed     Abstract available


  156. LEITER A, Kong CY, Gould MK, Kale MS, et al
    The benefits and harms of adjuvant chemotherapy for non-small cell lung cancer in patients with major comorbidities: A simulation study.
    PLoS One. 2022;17:e0263911.
    PubMed     Abstract available


  157. PHETPHOUNG T, Malla A, Rattanapisit K, Pisuttinusart N, et al
    Expression of plant-produced anti-PD-L1 antibody with anoikis sensitizing activity in human lung cancer cells via., suppression on epithelial-mesenchymal transition.
    PLoS One. 2022;17:e0274737.
    PubMed     Abstract available


  158. LIU BP, Zhang C, Zhang YP, Li KW, et al
    The combination of chronic stress and smoke exacerbated depression-like changes and lung cancer factor expression in A/J mice: Involve inflammation and BDNF dysfunction.
    PLoS One. 2022;17:e0277945.
    PubMed     Abstract available


  159. DENG J, Huang Y, Wu X, Hong Y, et al
    Comparison of dosimetric effects of MLC positional errors on VMAT and IMRT plans for SBRT radiotherapy in non-small cell lung cancer.
    PLoS One. 2022;17:e0278422.
    PubMed     Abstract available


  160. RAI SN, Das S, Pan J, Mishra DC, et al
    Multigroup prediction in lung cancer patients and comparative controls using signature of volatile organic compounds in breath samples.
    PLoS One. 2022;17:e0277431.
    PubMed     Abstract available


  161. GRUIONU LG, Udristoiu AL, Iacob AV, Constantinescu C, et al
    Feasibility of a lung airway navigation system using fiber-Bragg shape sensing and artificial intelligence for early diagnosis of lung cancer.
    PLoS One. 2022;17:e0277938.
    PubMed     Abstract available


  162. YAMAMOTO T, Katsuta Y, Sato K, Tsukita Y, et al
    Longitudinal analyses and predictive factors of radiation-induced lung toxicity-related parameters after stereotactic radiotherapy for lung cancer.
    PLoS One. 2022;17:e0278707.
    PubMed     Abstract available


  163. WANG L, Zhao X, Zheng H, Zhu C, et al
    AIF-1, a potential biomarker of aggressive tumor behavior in patients with non-small cell lung cancer.
    PLoS One. 2022;17:e0279211.
    PubMed     Abstract available


  164. WILLEN L, Berglund A, Bergstrom S, Isaksson J, et al
    Patterns of care and outcomes in immigrants with non-small cell lung cancer. A population-based study (Sweden).
    PLoS One. 2022;17:e0278706.
    PubMed     Abstract available


  165. LUCZYNSKI P, Poulin P, Romanowski K, Johnston JC, et al
    Tuberculosis and risk of cancer: A systematic review and meta-analysis.
    PLoS One. 2022;17:e0278661.
    PubMed     Abstract available


    January 2021
  166. HUH DA, Kang MS, Lee J, Choi JY, et al
    Occupational and environmental asbestos exposure and the risk of lung cancer in Korea: A case-control study in South Chungcheong Province of Korea.
    PLoS One. 2021;16:e0249790.
    PubMed     Abstract available


  167. NGUYEN RH, Vater LB, Timsina LR, Durm GA, et al
    Impact of smoke-free ordinance strength on smoking prevalence and lung cancer incidence.
    PLoS One. 2021;16:e0250285.
    PubMed     Abstract available


  168. DUMONT-LEBLOND N, Veillette M, Racine C, Joubert P, et al
    Non-small cell lung cancer microbiota characterization: Prevalence of enteric and potentially pathogenic bacteria in cancer tissues.
    PLoS One. 2021;16:e0249832.
    PubMed     Abstract available


  169. GOLDBERG E, Ievari-Shariati S, Kidane B, Kim J, et al
    Comparative metabolomics studies of blood collected in streck and heparin tubes from lung cancer patients.
    PLoS One. 2021;16:e0249648.
    PubMed     Abstract available


  170. NINOMIYA K, Arimura H, Chan WY, Tanaka K, et al
    Robust radiogenomics approach to the identification of EGFR mutations among patients with NSCLC from three different countries using topologically invariant Betti numbers.
    PLoS One. 2021;16:e0244354.
    PubMed     Abstract available


  171. PENG H, Sun H, Guo Y
    3D multi-scale deep convolutional neural networks for pulmonary nodule detection.
    PLoS One. 2021;16:e0244406.
    PubMed     Abstract available


  172. CAHUANA PINTO RSM, Castro Panzenhagen A, Silva Oliveira LF, Fonseca Moreira JC, et al
    Incidence of lung cancer and mortality among civil construction industry workers: A protocol for a systematic review and meta-analysis.
    PLoS One. 2021;16:e0250377.
    PubMed     Abstract available


  173. AYE PS, McKeage MJ, Tin Tin S, Khwaounjoo P, et al
    Population-based incidence rates and increased risk of EGFR mutated non-small cell lung cancer in Maori and Pacifica in New Zealand.
    PLoS One. 2021;16:e0251357.
    PubMed     Abstract available


  174. HO LJ, Yang HY, Chung CH, Chang WC, et al
    Increased risk of secondary lung cancer in patients with tuberculosis: A nationwide, population-based cohort study.
    PLoS One. 2021;16:e0250531.
    PubMed     Abstract available


  175. SAYANI A, Vahabi M, O'Brien MA, Liu G, et al
    Advancing health equity in cancer care: The lived experiences of poverty and access to lung cancer screening.
    PLoS One. 2021;16:e0251264.
    PubMed     Abstract available


  176. ALWITHENANI A, Bethune D, Castonguay M, Drucker A, et al
    Profiling non-small cell lung cancer reveals that PD-L1 is associated with wild type EGFR and vascular invasion, and immunohistochemistry quantification of PD-L1 correlates weakly with RT-qPCR.
    PLoS One. 2021;16:e0251080.
    PubMed     Abstract available


  177. DANG X, Zhao W, Li C, Yang H, et al
    Impact of COL6A4P2 gene polymorphisms on the risk of lung cancer: A case-control study.
    PLoS One. 2021;16:e0252082.
    PubMed     Abstract available


  178. ALLEN KL, Cann J, Zhao W, Peterson N, et al
    Correction: Upregulation of annexin A1 protein expression in the intratumoral vasculature of human non-small-cell lung carcinoma and rodent tumor models.
    PLoS One. 2021;16:e0252060.
    PubMed     Abstract available


  179. GOFFIN JR, Corriveau S, Tang GH, Pond GR, et al
    Management and outcomes of patients with chronic obstructive lung disease and lung cancer in a public healthcare system.
    PLoS One. 2021;16:e0251886.
    PubMed     Abstract available


  180. HEILBRONER SP, Xanthopoulos EP, Buono D, Carrier D, et al
    Efficacy and cost of high-frequency IGRT in elderly stage III non-small-cell lung cancer patients.
    PLoS One. 2021;16:e0252053.
    PubMed     Abstract available


  181. BARATA F, Fidalgo P, Figueiredo S, Tonin FS, et al
    Limitations and perceived delays for diagnosis and staging of lung cancer in Portugal: A nationwide survey analysis.
    PLoS One. 2021;16:e0252529.
    PubMed     Abstract available


  182. STEFANI D, Hegedues B, Collaud S, Zaatar M, et al
    Torque Teno Virus load in lung cancer patients correlates with age but not with tumor stage.
    PLoS One. 2021;16:e0252304.
    PubMed     Abstract available


  183. FRANCO F, Carcereny E, Guirado M, Ortega AL, et al
    Epidemiology, treatment, and survival in small cell lung cancer in Spain: Data from the Thoracic Tumor Registry.
    PLoS One. 2021;16:e0251761.
    PubMed     Abstract available


  184. ROUNIS K, Makrakis D, Papadaki C, Monastirioti A, et al
    Prediction of outcome in patients with non-small cell lung cancer treated with second line PD-1/PDL-1 inhibitors based on clinical parameters: Results from a prospective, single institution study.
    PLoS One. 2021;16:e0252537.
    PubMed     Abstract available


  185. NG WW, Lin CC, Cheng CY, Jiang JS, et al
    Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.
    PLoS One. 2021;16:e0253335.
    PubMed     Abstract available


  186. IKAWA T, Tabuchi T, Konishi K, Morimoto M, et al
    Prolonged overall treatment time negatively affects the outcomes of stereotactic body radiotherapy for early-stage non-small-cell lung cancer: A propensity score-weighted, single-center analysis.
    PLoS One. 2021;16:e0253203.
    PubMed     Abstract available


  187. TSAKANOVA G, Stepanyan A, Arakelova E, Ayvazyan V, et al
    The radioenhancement potential of Schiff base derived copper (II) compounds against lung carcinoma in vitro.
    PLoS One. 2021;16:e0253553.
    PubMed     Abstract available


  188. WRIGHT GM, Gimbrone NT, Sarcar B, Percy TR, et al
    CDK4/6 inhibition synergizes with inhibition of P21-Activated Kinases (PAKs) in lung cancer cell lines.
    PLoS One. 2021;16:e0252927.
    PubMed     Abstract available


  189. CHUNG HS, Bae S, Kim I, Ahn HY, et al
    Unexpected exposure to Mycobacterium tuberculosis during bronchoscopy using radial probe endobronchial ultrasound.
    PLoS One. 2021;16:e0246371.
    PubMed     Abstract available


  190. CHEN DT, Chan W, Thompson ZJ, Thapa R, et al
    Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.
    PLoS One. 2021;16:e0252041.
    PubMed     Abstract available


  191. BOROWICZ S, Principe DR, Dorman MJ, McHenry AJ, et al
    HAI-1 is an independent predictor of lung cancer mortality and is required for M1 macrophage polarization.
    PLoS One. 2021;16:e0252197.
    PubMed     Abstract available


  192. FUCHS J, Fruh M, Papachristofilou A, Bubendorf L, et al
    Resection of isolated brain metastases in non-small cell lung cancer (NSCLC) patients - evaluation of outcome and prognostic factors: A retrospective multicenter study.
    PLoS One. 2021;16:e0253601.
    PubMed     Abstract available


  193. XIAO K, Liu S, Xiao Y, Wang Y, et al
    Bioinformatics prediction of differential miRNAs in non-small cell lung cancer.
    PLoS One. 2021;16:e0254854.
    PubMed     Abstract available


  194. PEDERSEN S, Kristensen AF, Falkmer U, Christiansen G, et al
    Increased activity of procoagulant factors in patients with small cell lung cancer.
    PLoS One. 2021;16:e0253613.
    PubMed     Abstract available


  195. ARIK A, Dodd E, Cairns A, Streftaris G, et al
    Socioeconomic disparities in cancer incidence and mortality in England and the impact of age-at-diagnosis on cancer mortality.
    PLoS One. 2021;16:e0253854.
    PubMed     Abstract available



  196. Correction: Utilization of target lesion heterogeneity for treatment efficacy assessment in late stage lung cancer.
    PLoS One. 2021;16:e0255429.
    PubMed     Abstract available


  197. STIEB DM, Berjawi R, Emode M, Zheng C, et al
    Systematic review and meta-analysis of cohort studies of long term outdoor nitrogen dioxide exposure and mortality.
    PLoS One. 2021;16:e0246451.
    PubMed     Abstract available


  198. LIU X, Jia Y, Shi C, Kong D, et al
    CYP4B1 is a prognostic biomarker and potential therapeutic target in lung adenocarcinoma.
    PLoS One. 2021;16:e0247020.
    PubMed     Abstract available


  199. NONPANYA N, Sanookpan K, Joyjamras K, Wichadakul D, et al
    Norcycloartocarpin targets Akt and suppresses Akt-dependent survival and epithelial-mesenchymal transition in lung cancer cells.
    PLoS One. 2021;16:e0254929.
    PubMed     Abstract available


  200. HUANG L, Bommireddy R, Munoz LE, Guin RN, et al
    Expression of tdTomato and luciferase in a murine lung cancer alters the growth and immune microenvironment of the tumor.
    PLoS One. 2021;16:e0254125.
    PubMed     Abstract available


  201. PHAM DAT, Le SD, Doan TM, Luu PT, et al
    Standardization of DNA amount for bisulfite conversion for analyzing the methylation status of LINE-1 in lung cancer.
    PLoS One. 2021;16:e0256254.
    PubMed     Abstract available


  202. SUN Z, Nyberg R, Wu Y, Bernard B, et al
    Developing an enhanced 7-color multiplex IHC protocol to dissect immune infiltration in human cancers.
    PLoS One. 2021;16:e0247238.
    PubMed     Abstract available


  203. NAFIE E, Lolarga J, Lam B, Guo J, et al
    Harmine inhibits breast cancer cell migration and invasion by inducing the degradation of Twist1.
    PLoS One. 2021;16:e0247652.
    PubMed     Abstract available


  204. KINOSHITA F, Tagawa T, Yamashita T, Takenaka T, et al
    Prognostic value of postoperative decrease in serum albumin on surgically resected early-stage non-small cell lung carcinoma: A multicenter retrospective study.
    PLoS One. 2021;16:e0256894.
    PubMed     Abstract available


  205. ALOMAISH H, Ung Y, Wang S, Tyrrell PN, et al
    Survival analysis in lung cancer patients with interstitial lung disease.
    PLoS One. 2021;16:e0255375.
    PubMed     Abstract available


  206. PRAKASH MD, Stojanovska L, Feehan J, Nurgali K, et al
    Anti-cancer effects of polyphenol-rich sugarcane extract.
    PLoS One. 2021;16:e0247492.
    PubMed     Abstract available


  207. ANSAR A, Lewis V, McDonald CF, Liu C, et al
    Duration of intervals in the care seeking pathway for lung cancer in Bangladesh: A journey from symptoms triggering consultation to receipt of treatment.
    PLoS One. 2021;16:e0257301.
    PubMed     Abstract available


  208. BARMPOUTIS P, Di Capite M, Kayhanian H, Waddingham W, et al
    Tertiary lymphoid structures (TLS) identification and density assessment on H&E-stained digital slides of lung cancer.
    PLoS One. 2021;16:e0256907.
    PubMed     Abstract available


  209. AN G, Zhang Y, Chen N, Fu J, et al
    Opioid-free anesthesia compared to opioid anesthesia for lung cancer patients undergoing video-assisted thoracoscopic surgery: A randomized controlled study.
    PLoS One. 2021;16:e0257279.
    PubMed     Abstract available


  210. KAWAGUCHI Y, Hanaoka J, Ohshio Y, Okamoto K, et al
    Sarcopenia increases the risk of post-operative recurrence in patients with non-small cell lung cancer.
    PLoS One. 2021;16:e0257594.
    PubMed     Abstract available


  211. WINN CB, Hwang SK, Morin J, Bluette CT, et al
    Automated monitoring of respiratory rate as a novel humane endpoint: A refinement in mouse metastatic lung cancer models.
    PLoS One. 2021;16:e0257694.
    PubMed     Abstract available


  212. NODA-NARITA S, Kawachi A, Okuyama A, Sadachi R, et al
    First-line treatment for lung cancer among Japanese older patients: A real-world analysis of hospital-based cancer registry data.
    PLoS One. 2021;16:e0257489.
    PubMed     Abstract available


  213. CHMIELEWSKA I, Dudzinska M, Szczyrek M, Swirska J, et al
    Do endocrine adverse events predict longer progression-free survival among patients with non-small-cell lung cancer receiving nivolumab?
    PLoS One. 2021;16:e0257484.
    PubMed     Abstract available


  214. MOK PL, Anandasayanam ANK, Oscar David HM, Tong J, et al
    Lung development, repair and cancer: A study on the role of MMP20 gene in adenocarcinoma.
    PLoS One. 2021;16:e0250552.
    PubMed     Abstract available


  215. KREUS M, Lehtonen S, Skarp S, Kaarteenaho R, et al
    Extracellular matrix proteins produced by stromal cells in idiopathic pulmonary fibrosis and lung adenocarcinoma.
    PLoS One. 2021;16:e0250109.
    PubMed     Abstract available


  216. JUNG J, Lee YJ, Kim CH, Ahn S, et al
    Landscape of epigenetically regulated lncRNAs and DNA methylation in smokers with lung adenocarcinoma.
    PLoS One. 2021;16:e0247928.
    PubMed     Abstract available


  217. SHIMADA Y, Matsubayashi J, Saito A, Ohira T, et al
    Small RNA sequencing to differentiate lung squamous cell carcinomas from metastatic lung tumors from head and neck cancers.
    PLoS One. 2021;16:e0248206.
    PubMed     Abstract available


  218. DING J, Tu Z, Chen H, Liu Z, et al
    Identifying modifiable risk factors of lung cancer: Indications from Mendelian randomization.
    PLoS One. 2021;16:e0258498.
    PubMed     Abstract available


  219. VANECKOVA P, Wade S, Weber M, Murray JM, et al
    Birth-cohort estimates of smoking initiation and prevalence in 20th century Australia: Synthesis of data from 33 surveys and 385,810 participants.
    PLoS One. 2021;16:e0250824.
    PubMed     Abstract available


  220. BLASI MA, Maceroni M, Caputo CG, Sammarco MG, et al
    Clinical and ultrasonographic features of choroidal metastases based on primary cancer site: Long-term experience in a single center.
    PLoS One. 2021;16:e0249210.
    PubMed     Abstract available


  221. KATSURADA N, Tachihara M, Jimbo N, Yamamoto M, et al
    Yield of tumor samples with a large guide-sheath in endobronchial ultrasound transbronchial biopsy for non-small cell lung cancer: A prospective study.
    PLoS One. 2021;16:e0259236.
    PubMed     Abstract available


  222. XIAO K, Wang Y, Zhou L, Wang J, et al
    Construction of ceRNA network to identify the lncRNA and mRNA related to non-small cell lung cancer.
    PLoS One. 2021;16:e0259091.
    PubMed     Abstract available


  223. TAKAMORI S, Ohba T, Shimokawa M, Matsubara T, et al
    Prospective observational study of nutritional/immunologic indices as predictive biomarkers for the response to anti-PD-1 drugs in non-small cell lung cancer (ICI-PREDICT study).
    PLoS One. 2021;16:e0258616.
    PubMed     Abstract available


  224. ULLGREN H, Fransson P, Olofsson A, Segersvard R, et al
    Health care utilization at end of life among patients with lung or pancreatic cancer. Comparison between two Swedish cohorts.
    PLoS One. 2021;16:e0254673.
    PubMed     Abstract available


  225. MARFIL-SANCHEZ A, Seelbinder B, Ni Y, Varga J, et al
    Gut microbiome functionality might be associated with exercise tolerance and recurrence of resected early-stage lung cancer patients.
    PLoS One. 2021;16:e0259898.
    PubMed     Abstract available


  226. LIU Q, Tan C, Yi L, Wan X, et al
    Cost-effectiveness analysis of pembrolizumab plus chemotherapy as first-line therapy for extensive-stage small-cell lung cancer.
    PLoS One. 2021;16:e0258605.
    PubMed     Abstract available


  227. WANG H, Yang R, Jin J, Wang Z, et al
    Impact of concomitant idiopathic pulmonary fibrosis on prognosis in lung cancer patients: A meta-analysis.
    PLoS One. 2021;16:e0259784.
    PubMed     Abstract available


  228. LEISER D, Samanta S, Eley J, Strauss J, et al
    Role of caveolin-1 as a biomarker for radiation resistance and tumor aggression in lung cancer.
    PLoS One. 2021;16:e0258951.
    PubMed     Abstract available


  229. CHEN YL, Chen WL, Cheng YC, Lin MC, et al
    Development of a novel ALK rearrangement screening test for non-small cell lung cancers.
    PLoS One. 2021;16:e0257152.
    PubMed     Abstract available


  230. AIBA H, Kimura H, Yamada S, Okamoto H, et al
    Different patterns of pneumothorax in patients with soft tissue tumors treated with pazopanib: A case series analysis.
    PLoS One. 2021;16:e0254866.
    PubMed     Abstract available


  231. KENNEY J, Ndoye A, Lamar JM, DiPersio CM, et al
    Comparative use of CRISPR and RNAi to modulate integrin alpha3beta1 in triple negative breast cancer cells reveals that some pro-invasive/pro-metastatic alpha3beta1 functions are independent of global regulation of the transcriptome.
    PLoS One. 2021;16:e0254714.
    PubMed     Abstract available


  232. JENSEN SG, Epistolio S, Madsen CL, Kyneb MH, et al
    A new sensitive and fast assay for the detection of EGFR mutations in liquid biopsies.
    PLoS One. 2021;16:e0253687.
    PubMed     Abstract available


  233. LI A, Deng Y, Tan Y, Chen M, et al
    A novel miRNA-disease association prediction model using dual random walk with restart and space projection federated method.
    PLoS One. 2021;16:e0252971.
    PubMed     Abstract available


  234. MONTGOMERY MK, David J, Zhang H, Ram S, et al
    Mouse lung automated segmentation tool for quantifying lung tumors after micro-computed tomography.
    PLoS One. 2021;16:e0252950.
    PubMed     Abstract available


  235. BUSHEY RT, Gottlin EB, Campa MJ, Patz EF Jr, et al
    Complement factor H protects tumor cell-derived exosomes from complement-dependent lysis and phagocytosis.
    PLoS One. 2021;16:e0252577.
    PubMed     Abstract available


  236. LEE J, Bartholmai B, Peikert T, Chun J, et al
    Evaluation of Computer-Aided Nodule Assessment and Risk Yield (CANARY) in Korean patients for prediction of invasiveness of ground-glass opacity nodule.
    PLoS One. 2021;16:e0253204.
    PubMed     Abstract available


  237. KHAN SU, Ullah F, Mehmood S, Fahad S, et al
    Antimicrobial, antioxidant and cytotoxic properties of Chenopodium glaucum L.
    PLoS One. 2021;16:e0255502.
    PubMed     Abstract available


  238. HUNTER-SCHLICHTING D, Kelsey KT, Demmer R, Patel M, et al
    Cytomegalovirus infection in malignant pleural mesothelioma.
    PLoS One. 2021;16:e0254136.
    PubMed     Abstract available


  239. RICE SJ, Belani CP
    Diversity and heterogeneity of immune states in non-small cell lung cancer and small cell lung cancer.
    PLoS One. 2021;16:e0260988.
    PubMed     Abstract available


  240. YANG CZ, Hu LH, Huang ZY, Deng L, et al
    Comprehensive analysis of an immune infiltrate-related competitive endogenous RNA network reveals potential prognostic biomarkers for non-small cell lung cancer.
    PLoS One. 2021;16:e0260720.
    PubMed     Abstract available


  241. BRASSARD J, Gill ME, Bernatchez E, Desjardins V, et al
    Countering the advert effects of lung cancer on the anticancer potential of dendritic cell populations reinstates sensitivity to anti-PD-1 therapy.
    PLoS One. 2021;16:e0260636.
    PubMed     Abstract available


  242. CHOI W, Lee H
    Identifying disease-gene associations using a convolutional neural network-based model by embedding a biological knowledge graph with entity descriptions.
    PLoS One. 2021;16:e0258626.
    PubMed     Abstract available


  243. ISLAM MR, Hasan ATMK, Khatun N, Ridi IN, et al
    Demographic differentials of lung cancer survival in Bangladeshi patients.
    PLoS One. 2021;16:e0261238.
    PubMed     Abstract available


  244. DIAZ-ALVAREZ J, Roiz P, Gorospe L, Ayala A, et al
    Implementation of a lung cancer screening initiative in HIV-infected subjects.
    PLoS One. 2021;16:e0260069.
    PubMed     Abstract available


  245. SEN'KOVA AV, Savin IA, Brenner EV, Zenkova MA, et al
    Core genes involved in the regulation of acute lung injury and their association with COVID-19 and tumor progression: A bioinformatics and experimental study.
    PLoS One. 2021;16:e0260450.
    PubMed     Abstract available


  246. KARAMPINIS I, Rathmann N, Kostrzewa M, Diehl SJ, et al
    Computer tomography guided thoracoscopic resection of small pulmonary nodules in the hybrid theatre.
    PLoS One. 2021;16:e0258896.
    PubMed     Abstract available


  247. TORAL KJ, Wuenschel MA, Black EP
    Genomic data from NSCLC tumors reveals correlation between SHP-2 activity and PD-L1 expression and suggests synergy in combining SHP-2 and PD-1/PD-L1 inhibitors.
    PLoS One. 2021;16:e0256416.
    PubMed     Abstract available


  248. BREDNO J, Lipson J, Venn O, Aravanis AM, et al
    Clinical correlates of circulating cell-free DNA tumor fraction.
    PLoS One. 2021;16:e0256436.
    PubMed     Abstract available


  249. ABLE H, Wolf-Ringwall A, Rendahl A, Ober CP, et al
    Computed tomography radiomic features hold prognostic utility for canine lung tumors: An analytical study.
    PLoS One. 2021;16:e0256139.
    PubMed     Abstract available


  250. AIBA T, Hattori C, Sugisaka J, Shimizu H, et al
    Gene expression signatures as candidate biomarkers of response to PD-1 blockade in non-small cell lung cancers.
    PLoS One. 2021;16:e0260500.
    PubMed     Abstract available


  251. STAVEM K, Johannessen A, Nielsen R, Gulsvik A, et al
    Respiratory symptoms and respiratory deaths: A multi-cohort study with 45 years observation time.
    PLoS One. 2021;16:e0260416.
    PubMed     Abstract available


  252. DING M, Pan SY, Huang J, Yuan C, et al
    Optical coherence tomography for identification of malignant pulmonary nodules based on random forest machine learning algorithm.
    PLoS One. 2021;16:e0260600.
    PubMed     Abstract available


  253. SUN B, Zhao H
    The bioinformatics analysis of RIOX2 gene in lung adenocarcinoma and squamous cell carcinoma.
    PLoS One. 2021;16:e0259447.
    PubMed     Abstract available


  254. VELAZQUEZ FN, Zhang L, Viscardi V, Trocchia C, et al
    Loss of sphingosine kinase 1 increases lung metastases in the MMTV-PyMT mouse model of breast cancer.
    PLoS One. 2021;16:e0252311.
    PubMed     Abstract available


Thank you for your interest in scientific medicine.


AMEDEO Lung Cancer is free of charge.